National Registry of Prostate Carcinoma for the Assessment and Improvement of Cross-sectoral Quality of Care

National Registry of Prostate Carcinoma for the Assessment and Improvement of Cross-sectoral Quality of Care - d-uo-ProNAT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030737

Enrollment

6000

Registered

2022-11-22

Start date

2022-12-14

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Documentation of diagnostics, therapy and course of the disease

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Men with a proven prostate carcinoma - Age> = 18 years

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
I compliance with the guidelines 1) The actual use of guidelines in the therapy decision is unknown. Therefore, the frequency should be systematically recorded and evaluated in this register. End point: OS and CSS stratifies according to guideline adherence. No evaluation of individual medicines is sought. II professional disease 2) Professional risks for the development of prostate cancer have been described in the literature. However, there is hardly any data from the supply landscape in Germany. End point: Recording of professions in question with a risk of the development of prostate carcinoma. III early detection of prostate carcinoma 3) According to the S3 guideline, the implementation of an MPMRI should be carried out regularly when the prostate cancer is early. The frequency of using MPMRI before prostate tabiopsia in Germany is not known. End point: Entiring the use and the result of an MPMRT (Pirads 1-5) before the first biopsy of the prostate 4) Risk calculators and nomograms can avoid unnecessary prostate tabiopsia. The frequency and type of use of riskal culprits and nomograms in the daily practice routine is not known End point: Covering of the type of calculator/nomogram and the result before prostate tabiopsia IV therapy of locally limited prostate carcinoma 5) The use of decision -making aids to the therapy decision is recommended. The frequency and type of use of decision aids for the patient to facilitate the selection of curative therapy options is not known End point: Entiring the use and the result of decision aids before curative therapy 6) The importance of PSMA PET CTs before curative therapy in Germany is not known. End point: Entiring the implementation and results of a PSMA PET-CTS. In which cases influences/changes the result of this investigation alone. V Therapy of the progressive non-metastatic and metastatic prostate carcinoma 7) The PSA doubling time (PSA Time, PSADT) is a recognized risk factor and its calculation is a p	—

Measure

Time frame

I compliance with the guidelines 1) The actual use of guidelines in the therapy decision is unknown. Therefore, the frequency should be systematically recorded and evaluated in this register. End point: OS and CSS stratifies according to guideline adherence. No evaluation of individual medicines is sought. II professional disease 2) Professional risks for the development of prostate cancer have been described in the literature. However, there is hardly any data from the supply landscape in Germany. End point: Recording of professions in question with a risk of the development of prostate carcinoma. III early detection of prostate carcinoma 3) According to the S3 guideline, the implementation of an MPMRI should be carried out regularly when the prostate cancer is early. The frequency of using MPMRI before prostate tabiopsia in Germany is not known. End point: Entiring the use and the result of an MPMRT (Pirads 1-5) before the first biopsy of the prostate 4) Risk calculators and nomograms can avoid unnecessary prostate tabiopsia. The frequency and type of use of riskal culprits and nomograms in the daily practice routine is not known End point: Covering of the type of calculator/nomogram and the result before prostate tabiopsia IV therapy of locally limited prostate carcinoma 5) The use of decision -making aids to the therapy decision is recommended. The frequency and type of use of decision aids for the patient to facilitate the selection of curative therapy options is not known End point: Entiring the use and the result of decision aids before curative therapy 6) The importance of PSMA PET CTs before curative therapy in Germany is not known. End point: Entiring the implementation and results of a PSMA PET-CTS. In which cases influences/changes the result of this investigation alone. V Therapy of the progressive non-metastatic and metastatic prostate carcinoma 7) The PSA doubling time (PSA Time, PSADT) is a recognized risk factor and its calculation is a p

—

Secondary

Measure	Time frame
Please see primary end point	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 5, 2026